FTRSS enterprisetomorrow Custom RSS Feed for widget #25817

  • Tianneng Attends the Intersolar 2024
    on June 24, 2024 at 12:24 am

    MUNICH, June 24, 2024 /PRNewswire/ — From June 19 to 21, 2024, the New International Exhibition Center in Munich, Germany, welcomed the world’s leading solar photovoltaic energy storage exhibition – Intersolar 2024. Tianneng group launched three cutting-edge solutions at the exhibition: small-scale industrial and commercial energy storage system, utility-scale energy storage system and communication energy storage system, demonstrating its innovative strength in the energy field.Tianneng group’s 100KW liquid-cooled industrial and commercial energy storage cabinet solution is designed for enterprise users. It has performance characteristics such as fast cooling, a power factor of 99%, and supports parallel use for expansion, aiming to provide efficient and reliable energy storage services. From battery cells to systems, all-round protection of system security. Full-process services, optimize energy management, help reduce operating costs, and create high-quality low-carbon electricity services for users. As the world’s leading new energy full industry chain solution provider, Tianneng Group relies on 38 years of industry experience to define new energy solution capabilities from the “core”. Tianneng group has strong expertise in self-produced batteries, modules and integrated solutions With leading advantages, it has significant competitiveness in terms of overall project quality and delivery capabilities. Through continuous technological innovation and high-quality services, we help customers achieve more efficient and greener energy management. In the future, Tianneng Group will also work with partners and customers from all over the world to conduct in-depth exchanges and jointly explore more possibilities in the energy field.  View original content: SOURCE Tianneng

  • Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
    on June 24, 2024 at 12:15 am

    ROCKVILLE, Md. and SUZHOU, China, June 24, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK) announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American depositary shares representing its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to occur after the SEC completes its review process, subject to market and other conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.View original content to download multimedia: SOURCE Ascentage Pharma

  • TradeFlow Capital Management Celebrates its entry into the 7th successful year of its USD Fund with consistent growth and continued innovation
    on June 24, 2024 at 12:00 am

    SINGAPORE, June 24, 2024 /PRNewswire/ — TradeFlow Capital Management (TradeFlow), a global leader in alternative trade finance solutions, is proud to announce the continued success of its USD Trade Flow Fund as it enters the 7th year of generating strong and stable returns. Since its inception, the Fund has grown steadily, built on a strong asset-backed base with the exciting implementation of Fintech allowing the creation of new digital assets that enhance liquidity.   The USD Trade Flow Fund, launched in April 2018, was designed to narrow the trade finance gap faced by SMEs worldwide with low volatility and strong and stable returns in mind, whilst facilitating trade that would not otherwise be transacted. Since its inception, the Fund has exceeded its objectives, demonstrating resilience and stability in a dynamic and challenging global commodities market, ensuring the flow of economic essentials such as metals, grains and fuels. To date, through its USD Trade Flow fund (and EURO Trade Flow Fund launched in November 2020), TradeFlow has successfully invested in more than US$3.5 Bn of physical commodity trade through 3500+ transactions across 18+ countries and 35+ commodity types, with more than 1800 SME counterpart entities KYC reviewed. The Trade Flow fund strategy is also shariah compliant for murabaha transactions. These achievements have been made possible by strategic efforts to embrace the latest in Digitalization technologies available to streamline all of TradeFlow’s operations, including the storage and movement of all commodities enabled.  Continuously pioneering cutting-edge financial solutions, TradeFlow has enhanced its proprietary platform to streamline operations and improve transparency for investors. As part of its business model, TradeFlow Capital has integrated Environmental, Social, and Governance (ESG) principles into its investment strategy, reinforcing its commitment to sustainable and responsible investing into every trade. Since December 2020, all of our shipping has been carbon neutral through offsetting emissions via verified carbon credit projects. Dr. Tom James, CEO and CIO of TradeFlow, shared his excitement about this milestone: “Reaching the 7th year of our USD Fund is a testament to the dedication and hard work of our team, the trust of our investors, and the enduring need for innovative trade finance solutions. We are incredibly proud of what we have achieved and are more motivated than ever to continue driving growth and creating value for our stakeholders.” John Collis, Chief Risk Officer and Chief Legal Officer of TradeFlow, added: “Our success over these past seven years underscores our robust risk management framework and our commitment to legal and regulatory compliance. We’ve built a solid foundation that safeguards our investors’ interests and also supports sustainable growth. Looking ahead, we remain dedicated to maintaining the highest standards of integrity and compliance in all our operations.” Looking ahead, TradeFlow remains committed to delivering greater value to Investors and positive impact to SMEs and local communities by expanding its global footprint, enhancing its technological capabilities, and further strengthening  TradeFlow’s  position as a market leader and innovator in the trade finance sector. About TradeFlow Capital Management (TradeFlow) TradeFlow is the world’s leading and first Fintech-powered commodity trade fund manager, enabling the import/export physical commodity transactions for SME size firms by employing its unique non-credit lending approach to trade finance.  TradeFlow consists of a diverse team of experts with the focused mission of addressing the increasing trade finance gap (US$2.5 Trillion) faced by global SMEs operating as producers/traders/end-users in the bulk commodity trading space. By performing an enabling role in international trade and globalization, TradeFlow creates stable asset backed returns for its investors, opportunities for businesses and growth for economies. TradeFlow is a Partner of the International Chamber of Commerce (ICC) to mobilise capital and improve trade finance access for SMEs worldwide through the “‘ICC Trade Now” and “ICC Digital Trade Standards Initiative” platforms. For more information, please visit: or email us at original content to download multimedia: SOURCE TradeFlow Capital Management

  • Juniper Biologics Expands Distribution Rights for Caris Life Sciences’ Molecular Profiling in the Middle East and Africa
    on June 23, 2024 at 12:02 pm

    SINGAPORE, June 23, 2024 /PRNewswire/ — Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)’ solid tumour molecular profiling services in the Middle East and Africa (MEA). Caris is the leading next-generation AI TechBio company and precision medicine pioneer. This expansion follows the initial January 2023 distribution rights partnership with Caris for the same services in Southeast Asia (SEA). Juniper is now poised to offer Caris’ advanced solid tumour molecular profiling services across a broader region, enhancing patient access to personalised treatment options.Caris’ best-in-class molecular profiling, combined with proprietary artificial intelligence, provides more precise and individualized cancer treatments. This profiling approach assesses DNA, RNA, and proteins, revealing a molecular blueprint that identifies treatment options specific to each patient’s cancer. Caris has developed the world’s largest and most informative platform for cancer analysis, featuring the most advanced tumour profiling available, including Whole Exome and Whole Transcriptome Sequencing across over 23,000 genes. By analysing biomarkers found in tumours, Caris helps healthcare providers make informed choices for personalised care. Juniper Biologics is committed to driving positive change in the pharmaceutical industry on a global scale. Aligned with its mission to deliver transformative therapies through bold scientific innovation, Juniper’s collaboration with Caris will enhance access to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful partnerships aimed at uplifting communities and individuals, especially in underserved regions where access to advanced therapies is limited. Raman Singh, Founder and Chief Executive Officer (CEO) of Juniper Biologics, spoke on the successful acquisition: “Caris molecular profiling bridges the gap between tumour biology and cancer treatments, guiding precision medicine through personalised treatment selection for physicians and their patients. Our exclusive partnership with Caris Life Sciences to distribute this service in the Middle East and Africa will significantly empower healthcare professionals to make informed decisions for their patients. This service enables oncologists to recommend highly personalised treatments that specifically target a patient’s cancer, thereby improving and expanding their care options. This targeted approach offers patients, particularly those with rare or aggressive cancers, an improved quality of life.” “Caris is pleased to expand the distribution of our molecular profiling services in the Middle East and Africa through our partnership with Juniper Biologics,” said Caris President David Spetzler, MS, PhD, MBA. “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.” This partnership marks a significant milestone in expanding access to personalised medicine and advanced cancer treatment technologies in the Middle East and Africa. About Juniper Biologics Backed by The Sylvan Group, Juniper Biologics is a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients, by building a growing presence in Oncology and Oncology Supportive Care, Rare/Orphan Diseases and Gene Therapy. It was founded on a vision to provide treatments for unmet medical needs focused on specialist therapy areas in which it can make the most difference. Through bold and transformative science, Juniper Biologics is committed to creating possibilities that have the potential to become the next generation of life-changing medicines for patient communities in China, Japan, Asia, Australia, New Zealand, Middle East, and Africa. Website: LinkedIn: About Caris Life SciencesCaris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyse and unravel the molecular complexity of disease. This convergence of sequencing power, big data, and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection, and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia, and other international markets. To learn more, please visit   SOURCE Juniper Biologics

  • Jointly Embarking on a New Chapter: Huawei Consumer Cloud Services and Malaysia Airlines Collaborate to Expand the Chinese Outbound Travel Market
    on June 23, 2024 at 11:17 am

    DONGGUAN, China, June 23, 2024 /PRNewswire/ — Huawei Consumer Cloud Services and Malaysia Airlines have decided to enter a strategic partnership in penetrating Chinese Outbound Travel market. This highly anticipated collaboration was officially announced during the signing ceremony at Huawei’s 2024 Developer Conference. This historic moment was held at the Huawei Developer Conference 2024, adding a highlight to the over 100 exciting events.Through Huawei Consumer Cloud Services’ advertising platform, Malaysia Airlines will achieve comprehensive digitization of its aviation services. Through data-driven personalized recommendations and precise advertising placements, it will achieve deeply customized marketing effects. This will allow Malaysia Airlines to not only gain insights into travelers’ needs but also grasp market trends, truly embodying a customer-centric service philosophy. The comfortable start to a journey is precisely where Huawei Consumer Cloud Services, as part of the 1+8+N all-scenario ecosystem and media marketing capability, provides advertising marketing and traffic monetization services for advertisers and traffic alliances. This partnership enables Huawei and Malaysia Airlines to jointly provide travelers with one-stop, full-cycle, and personalized travel services. While meeting travelers’ needs throughout their journey, the two parties have deepened their cooperation, forming a strong win-win situation. As an industry leader in technological innovation, Huawei remains committed to an open ecosystem, providing Malaysia Airlines with advertising marketing and traffic monetization services through its Petal Ads platform, helping it further expand in the Chinese market. This partnership is a strategic decision made by both companies to better serve consumers based on consumer demand. Mr. Vincent Wen, Director of Cloud Service Business Growth of Huawei, said, ” We are committed to strengthening our partnership with Malaysia Airlines by leveraging our extensive expertise in telecommunications infrastructure, digital solutions, and our deep understanding of the Chinese market. Through collaborative efforts focused on localized strategies and by harnessing Huawei’s robust brand presence and marketing channels in China, Malaysia Airlines can significantly enhance its visibility and market penetration among Chinese travellers. This strategic alignment between Huawei and Malaysia Airlines combines technological prowess, market expertise, and innovation, opening up exciting opportunities in the dynamic Chinese tourism landscape.” The joint collaboration of MH and Huawei also introduce a young traveler program MHexplorer, empowering young generation to explore the world and broaden their horizons. It incorporated Huawei Consumer Cloud Services’ resource advantage to drive the marketing strategy to ultimate effectiveness and promote the expansion of Malaysia Airlines in the Chinese and Asia-Pacific market. It aims that the perks and conveniences brought by the MHexplorer project will fulfill the yearning for world travel in every young individual’s heart. It also serves as an advocacy and active promotion of the idea. Mr. Ahmad Luqman Mohd Azmi, Chief Executive Officer of Malaysia Aviation Group (MAG), said, “We are delighted to join forces with Huawei by leveraging their digital capabilities to expand our reach within the APAC region. This strategic partnership aims to elevate our efforts in customer engagement by providing highly personalized experiences and innovative solutions tailored to meet the unique needs of the market. We look forward to exploring new avenues and opportunities that will solidify the Malaysia Airlines position in the region and extend our influence globally as the gateway to Asia and beyond.” This remarkable collaboration not only showcases the profound cooperation between Huawei Consumer Cloud Services and Malaysia Airlines but also brings a novel aviation travel experience for consumers. In the future, Huawei and Malaysia Airlines will continue to explore and innovate, striving for the development of the global tourism market together. Everything centered around customers, and with continual technological innovation, sincerity, passion, and diligence, they present a broader blue sky to the world.  View original content to download multimedia: SOURCE Huawei Mobile Services